Algert Global LLC Jounce Therapeutics, Inc. Transaction History

Algert Global LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $93,604 - $256,408	33,430 New	33,430 $101,000
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $72,522 - $98,328	-10,200 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $51,408 - $89,046	10,200 New	10,200 $76,000
Q3 2020 Nov 16, 2020	SELL	$4.58 - $10.95 $124,072 - $296,635	-27,090 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$4.17 - $7.58 $55,544 - $100,965	-13,320 Reduced 32.96%	27,090 $187,000
Q1 2020 May 13, 2020	BUY	$2.91 - $8.7 $43,941 - $131,370	15,100 Added 59.66%	40,410 $192,000
Q3 2019 Nov 14, 2019	SELL	$3.33 - $4.93 $13,486 - $19,966	-4,050 Reduced 13.79%	25,310 $84,000
Q2 2019 Aug 14, 2019	BUY	$4.3 - $6.73 $65,265 - $102,147	15,178 Added 107.02%	29,360 $145,000
Q1 2019 May 01, 2019	BUY	$3.43 - $6.87 $48,644 - $97,430	14,182 New	14,182 $88,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.